Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.3 Top Oil & Gas MLPs to Consider with Dividend Yields Above 5%
3 Reasons Why Growth Investors Shouldn't Overlook Global Partners (GLP)
Lilly's Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance
Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs
GLP-1 weight loss drugs effective even at low starter doses
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
GLP-1 Coverage Fell From 72% to 60%. Is Eli Lilly's Weight-Loss Boom Hitting an Insurance Wall?
Should Value Investors Buy Global Partners (GLP) Stock?
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren't the Reason
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
GLP-1 maker hit with 'sell' rating as 2027 revenue cliff fears mount
IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers
Lilly's GLP-1 pill hits UK pharmacies as US battle with Novo intensifies
Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030